CRISPR/Cas9 Knockout Cell Lines and Lysates

(PresseBox) ( Frankfurt, )
AMSBIO has established a comprehensive portfolio of knock-out cell lines and lysates generated with CRISPR/Cas9 technology.

Using CRISPR/Cas9 gene editing technology for the generation of knock-out cell lines and cell lysates ensures the development of useful tools to validate antibody specificity and elucidate gene function. Knock-out cell lines and cell lysates are widely agreed to be the best negative controls to quickly and confidently prove an antibody’s specificity for a target of interest and ensure reproducibility.

Generated in the most widely used HEK293T, HeLa, and A549 cell lines, AMSBIO gene edited homozygous knock-out cell lines work in the cells you know and trust. Consequently, you are no longer limited to highly specialized and altered backgrounds. AMSBIO offers only 100% knock-out clonal lines meaning you don't have to work with pools of cells containing only a percentage of knockout cells.

Knock-out cell lysates from AMSBIO are made from double knock-out cell lines and provide the perfect negative control for Western Blots to validate the specificity of antibodies or be used in functional assays. Each AMSBIO knock-out cell lysate product comes with a cell-line matched wild type control.

For further information please visit http://www.amsbio.com/crispr-knock-out-cell-lines-lysates.aspx or contact AMSBIO on +44-1235-828200 / +1-617-945-5033 / info@amsbio.com.

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. This expertise in cell culture and the ECM allows AMSBIO to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics.

For drug discovery research, AMSBIO offers assays, recombinant proteins and cell lines. Drawing upon a huge and comprehensive biorepository, AMSBIO is widely recognised as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cell and cell therapy applications these include high quality solutions for viral delivery (lentivirus, adenovirus and adeno-associated virus) in addition to GMP cryopreservation technology. For further information please visit www.amsbio.com. 
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to service@pressebox.de.